Organization | Weifang Medical University

Weifang Medical University Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2016

NCT02985372

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Affiliated Hospital of Weifang Medical University | Weifang Medical University

Active Ingredients

Drugs in Phase 4 Trials (5)

allogeneic cord blood (1 trial)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

cyclosporine (sandimmune) (1 trial)

tegoprazan (1 trial)

Drugs in Phase 3 Trials (2)

cytarabine (cytosar-u) (1 trial)

decitabine (dacogen) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 4)

Anemia, Aplastic (Phase 4)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 7